Lung Cancer

Second cancers are common among patients with lung cancer, so how can risk be lowered?

Immune and targeted therapies build hope for patients with advanced lung cancer.

The combination of immunotherapy and chemotherapy, and more, is changing the landscape of the disease.

The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), according to Merck (MSD), the manufacturer of the PD-1 inhibitor.

The Food and Drug Administration (FDA) approved Tagrisso as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations.

The Food and Drug Administration (FDA) granted priority review to a supplemental biologics license application for Opdivo (nivolumab) for the treatment of patients with small cell lung cancer with disease progression following two or more lines of therapy.

Most recently, the dynamic duo of Yervoy (ipilimumab) plus Opdivo (nivolumab) – both checkpoint inhibitors – extended average progression-free survival (PFS) rates more than three times than standard-of-care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB).

Some patients with incurable non-small cell lung cancer (NSCLC) should receive chemotherapy concurrent with palliative thoracic radiation therapy, according to an updated guideline released by the American Society for Radiation Oncology (ASTRO).

New targeted therapies and immunotherapy treatments have rapidly improved the outcomes of patients with cancer. But not everyone is so lucky to have access to these agents.

FDA approves first treatment approved for stage 3 unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation.

Roswell Park Cancer Center researchers shed light on disease incidence among women.

Lorlatinib was granted a priority review to a new drug application (NDA) for patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on one or more ALK tyrosine kinases inhibitors (TKIs).

Lung cancer is the leading cause of cancer-related death for women in the United States, but often does not get as much attention as other malignancies. In an effort to change that, and to one day decrease the number of women who are dying from the disease, the bipartisan Women and Lung Cancer Research and Preventative Services Act was reintroduced into Congress.

A new study showed that a large percentage of patients do not receive standard-of-care.

Not all patients with non-small cell lung cancer (NSCLC) respond to immunotherapy, so researchers are exploring the use of combination regimens, including immune checkpoint inhibitors and chemotherapy, to improve outcomes in these patients.

Throughout her life and especially in her fight against lung cancer, Mom set us an example in unconditional devotion, taught our family valuable life lessons and never lost her indomitable spirit.

The Food and Drug Administration (FDA) expanded the approved use for Gilotrif (afatinib). The drug can now be used to treat patients with metastatic non-small cell lung cancer (NSCLC) who have uncommon EGFR alterations in L861Q, G719X and/or S768I.

A four-drug combination, including Tecentriq (atezolizumab), Avastin (bevacizumab), carboplatin and paclitaxel, delayed progression or death by 38 percent in patients with advanced non-squamous non–small cell lung cancer (NSCLC), compared to those who were treated with Avastin alone.

Although ROS1 mutations are quite rare in patients with non-small cell lung cancer (NSCLC), testing for the mutation in all who have the disease is important, as it can play a vital role in determining a treatment plan.

Imfinzi (durvalumab), a PD-L1 inhibitor, is being reviewed for a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) for the treatment of patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The sBLA is in light of positive progression-free survival (PFS) results from the phase 3 PACIFIC trial.

Frontline Tagrisso (osimertinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) to treat patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations (exon 19 deletions or exon 21 [L858R] substitution mutations).

There has been a “renaissance” in the treatment strategies of patients with non-small cell lung cancer (NSCLC) who have EGFR-mutation–positive disease, Edward S. Kim, M.D.

Clinical trials of combination immunotherapy treatments are showing impressive overall survival rates.

Alecensa (alectinib) was granted approval by the Food and Drug Administration (FDA) to treat patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor.

More patients with non-small cell lung cancer (NSCLC) should be evaluated and referred to clinical trials, especially those who may have molecular abnormalities, says Victoria M. Villaflor, M.D.